Navigation Links
Ranbaxy and Pfizer Settle Lipitor Litigation Worldwide
Date:6/18/2008

Ranbaxy Will Market Generic Atorvastatin in the U.S. With 180 Days

Exclusivity From Nov. 30, 2011

Agreement Also Resolves Caduet, Accupril Litigation in the US

GURGAON, Harayana, India and PRINCETON, N.J., June 18 /PRNewswire/ -- Ranbaxy Laboratories Limited (Ranbaxy), announced today that it has entered into an agreement with Pfizer Inc. to settle most of the patent litigation worldwide involving Atorvastatin (Lipitor), the world's most-prescribed cholesterol-lowering medicine. This decision will allow for an earlier introduction of a generic formulation that will benefit patients and many healthcare systems throughout the world. Lipitor is the world's largest selling drug with worldwide sales in 2007 of $12.7 billion.

The agreement pertains solely to Ranbaxy and its affiliates and does not cover legal challenges to the Lipitor patents involving other generic manufacturers. However, as Ranbaxy was the first generic challenger to the listed Lipitor patents, it retains the right to the marketing exclusivity of 180 days in the United States. Under the terms of the agreement, Ranbaxy will have a license to sell generic versions of Atorvastatin and the fixed-dose combination of Atorvastatin-Amlodipine besylate in the United States effective Nov. 30, 2011.

Welcoming the development, Malvinder Mohan Singh, CEO and MD, Ranbaxy Laboratories Ltd., said, "This comprehensively settles outstanding issues between Ranbaxy and Pfizer bringing to closure a number of ongoing patent disputes. It also provides certainty and visibility to the launch of Ranbaxy's Generic Atorvastatin, with 180-day market exclusivity in the US and an early entry in other markets. This will make the worlds largest selling drug more accessible to patients who will gain from the timely availability of an affordable quality option."

Ranbaxy will also have a license to sell Atorvastatin on varying dates in an additional 7 countries, includi
'/>"/>

SOURCE Ranbaxy Laboratories Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Ranbaxy to Bring in Daiichi Sankyo as Majority Partner; Strategic Combination Creates Innovator and Generic Pharma Powerhouse
2. Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Oral Solution
3. Ranbaxy Gains Approval to Manufacture and Market Cefuroxime Axetil for Oral Suspension
4. Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Tablets (OTC), 5mg and 10mg
5. Ranbaxy Receives Tentative Approval For Valsartan Tablets
6. Ranbaxy First to Gain Approval to Manufacture and Market Clarithromycin for Oral Suspension, USP
7. Ranbaxy Gains Approval to Manufacture and Market Carvedilol Tablets in the U.S. Market
8. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
9. Novartis, Pfizer and Merck Take the Lead on Strong Relationships with Physicians, as Doctors Demand an Expanding Set of Services
10. Pfizers work on penicillin for World War II becomes a National Historic Chemical Landmark
11. AUDIO from Medialink and Pfizer: Free Programs for Uninsured Men and Women Who Need Help Paying for Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014 Farmington Company today announced ... mission and visual identity helping brokers, consultants and ... them to create greater benefit communication synergies. They ... on empowering customers to better leverage Farmington Company’s ... jewel of the rebrand is the refreshed tagline: ...
(Date:10/1/2014)... Beverly Hills licensed Clinical Psychologist and nationally ... years of private practice in her Beverly Hills office ... greater joy and fulfillment in their relationships. Dr. Mojas ... suggestions for anyone who suspects they are in a ... or not, it’s not always easy to know when ...
(Date:10/1/2014)... 01, 2014 Diet Doc understands that many ... lose weight and their dieting attempts could be easily sabotaged ... hormone diet treatments into their programs as a ... see fast and effective weight loss results, it also allows ... habits to maintain their weight for the future. , Earlier ...
(Date:10/1/2014)... 2014 Scientists at the University of ... target immune system proteins has the power to knock ... details of the new study on their website. ... Researchers in the UWA School of Pathology and Laboratory ... mice with mesothelioma with promising results. , “A ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Nordic ... benefit a very special cause. The campaign—“Buy One ... for Paws for Veterans, a nonprofit organization that ... also rescuing shelter dogs that would otherwise face ... featured products will support monthly donations of Nordic ...
Breaking Medicine News(10 mins):Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2Health News:Nordic Naturals® Inspires Support for Paws for Veterans -- ‘Buy One Bottle. Help Two Heroes.’ Initiative Kicks Off October 1 2
... against cancer is not won in a single battle: Long after ... reason for this is under debate, and much is unclear. New ... one type of blood cancer, the source of cancer recurrence is ... as regular cancer cells, and thus able to survive chemotherapy. The ...
... between high levels of the environmental toxin PCB and the ... in a new study published today in the scientific journal ... the risk of diabetes and high blood pressure, among other ... more dangerous that fat near the surface of the body ...
... HealthDay Reporter , MONDAY, May 28 (HealthDay ... menopausal women presents good news for those at risk ... breast cancer and other chronic diseases. While estrogen-only ... increase the odds for stroke and other conditions including ...
... Steven Reinberg HealthDay Reporter , MONDAY, May 28 ... than twice a week might be increasing their risk for ... to be cumulative and highest among women who describe themselves ... "About 10 to 20 percent of women in modern ...
... other similar painkillers may help protect against skin cancer. ... journal of the American Cancer Society, the findings indicate ... benefits of these commonly used medications. Previous studies ... include aspirin, ibuprofen, and naproxen, as well as a ...
... Reporter , MONDAY, May 28 (HealthDay News) -- Could your ... sit around? A small study suggests it,s possible: Kids ... hung out with active kids, and the reverse was true, ... how active kids are, and it,s not clear whether there,s ...
Cached Medicine News:Health News:Why chemotherapy fails 2Health News:Why chemotherapy fails 3Health News:PCB can increase risk of abdominal fat 2Health News:HRT Update: Therapy May Reduce Fractures, Boost Some Risks 2Health News:HRT Update: Therapy May Reduce Fractures, Boost Some Risks 3Health News:Night Shift Might Boost Women's Breast Cancer Risk: Study 2Health News:Night Shift Might Boost Women's Breast Cancer Risk: Study 3Health News:Night Shift Might Boost Women's Breast Cancer Risk: Study 4Health News:Commonly used painkillers may protect against skin cancer 2Health News:Key to More Active, Slimmer Kids: Friends 2
(Date:10/1/2014)... 2014 Quantum Materials Corp (OTCQB:QTMM) today ... photoactive quantum dots for use in next-generation ... advantages for solar power generation, the high cost ... dots with which to develop thin film solar ... utilization and acceptance. The company is also seeking ...
(Date:10/1/2014)... WOONSOCKET, R.I. , Oct. 1, 2014  CVS ... Pharmacists Month for their role in changing the way ... and improve quality in the Company,s retail pharmacies, mail ... "Last month, we changed our company name to CVS ... our expertise in driving the innovations needed to shape ...
(Date:9/30/2014)... , Sept. 30, 2014 This report analyzes ... by the following Product Categories: Enteral Feeding Pumps, Nasogastric Tubes, ... for the US Canada, Japan , ... Latin America , and Rest of World. Annual ... 2018. Also, a six-year historic analysis is provided for these ...
Breaking Medicine Technology:Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 2CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 3Global Enteral Feeding Devices Industry 2Global Enteral Feeding Devices Industry 3Global Enteral Feeding Devices Industry 4Global Enteral Feeding Devices Industry 5Global Enteral Feeding Devices Industry 6Global Enteral Feeding Devices Industry 7Global Enteral Feeding Devices Industry 8Global Enteral Feeding Devices Industry 9Global Enteral Feeding Devices Industry 10Global Enteral Feeding Devices Industry 11Global Enteral Feeding Devices Industry 12Global Enteral Feeding Devices Industry 13Global Enteral Feeding Devices Industry 14Global Enteral Feeding Devices Industry 15Global Enteral Feeding Devices Industry 16Global Enteral Feeding Devices Industry 17Global Enteral Feeding Devices Industry 18Global Enteral Feeding Devices Industry 19
... (NASDAQ: PRXL ) today reported financial results ... 30, 2011.   For the three months ... 5.2% to $310.5 million compared with $295.3 million in ... foreign exchange movements in the quarter of $12.0 million, ...
... Styron, the global materials company and manufacturer of ... its EMERGE™ Advanced Resins family in North America. ... is a polycarbonate blend with superior chemical resistance ... (Logo: http://photos.prnewswire.com/prnh/20110809/CL49820LOGO) "With an ...
Cached Medicine Technology:PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 2PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 3PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 4PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 5PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 6PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 7PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 8PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 9PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 10PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 11PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 12PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results 13Styron Introduces Chemical Resistance Blends for Medical Housings 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... the nutrients used in the ARED study, ... Trial (LAST), which suggested no AMD disease ... one year period. Macula Complete also contains ... studies to support the mitochondria, as well ...
Medicine Products: